NRG-BR001 and NRG-BR002 PowerPoint Presentation
Principal Investigator/Co-Principal Investigator
Steven Chmura, MD, PhD
Julia R. White, MD
Phase II-R: To determine whether ablation (through SBRT and/or surgical resection of all known metastases) in oligometastatic breast cancer patients provides a sufficient signal for improved progression-free survival (PFS) to warrant full accrual to the Phase III portion of the trial.
Phase III: To determine whether ablation (through SBRT and/or surgical resection of all known metastases) in oligometastatic breast cancer patients significantly improves overall survival (OS)
Patients with locally controlled metastatic breast cancer with the following number of allowable metastases:
≤ 4 metastases seen on standard imaging within 60 days prior to registration when all metastatic disease is located within the following sites: peripheral lung; osseous (bone); spine
≤ 2 metastases seen on standard imaging within 60 days prior to registration when any one metastasis is located in one of the following sites: liver; central lung; mediastinal/cervical lymph node; abdominal-pelvic metastases (lymph node/adrenal gland)
and at least 1 pathologically confirmed visualized on CT or PET/CT.
402 patients (including the 146 already accrued in the Phase II-R portion)
Activated December 24, 2014
The protocol and related documents are available at the National Cancer Institute Cancer Trials Support Unit (CTSU) website.
RT Credentialing and Treatment Planning Materials
Click here to visit the IROC website for extensive information about benchmark case planning, credentialing, and treatment planning guidelines.